The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis

Pedro N. Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, Gilberto De Lima Lopes, Bruno Andraus Filardi, Pedro Oliveira, Giannis Mountzios, Ramon Andrade De Mello

Research output: Contribution to journalArticle

Abstract

Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p <0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

Original languageEnglish (US)
Pages (from-to)479-488
Number of pages10
JournalImmunotherapy
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

    Fingerprint

Keywords

  • anti-PDL1
  • clinical trials
  • lung cancer
  • meta-analysis
  • nivolumab
  • non-small-lung cancer
  • PD1
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Aguiar, P. N., Santoro, I. L., Tadokoro, H., De Lima Lopes, G., Filardi, B. A., Oliveira, P., ... De Mello, R. A. (2016). The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis. Immunotherapy, 8(4), 479-488. https://doi.org/10.2217/imt-2015-0002